STOCK TITAN

Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) announced participation in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on November 18, 2021. Key executives, including Bill Peters and Dan Dischner, will present a pre-recorded session available at 8:00 am GMT. The event will be accessible for 90 days via the company's website. Amphastar specializes in developing and manufacturing generic and proprietary injectable and inhalation products, primarily for hospital and urgent care settings.

Positive
  • None.
Negative
  • None.

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 11, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference. This presentation will be pre-recorded and made available November 18, 2021 at 8:00 am GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 90 days following the presentation.

Amphastar Pharmaceuticals, Inc.

About Amphastar:

Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company's website at www.amphastar.com.

The Amphastar Pharmaceuticals' logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene MIST®, Amphadase® and Cortrosyn®, are the property of Amphastar Pharmaceuticals, Inc.

Forward Looking Statements

All statements in this press release that are not historical are forward-looking statements. These statements are not historical facts but rather are based on Amphastar's historical performance and its current expectations, estimates, and projections regarding Amphastar's business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in the Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 15, 2021. You can locate these reports through the Company's website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause Amphastar's expectations to change.

CONTACT:
Bill Peters
Chief Financial Officer
(909) 476-3416

SOURCE: Amphastar Pharmaceuticals, Inc.



View source version on accesswire.com:
https://www.accesswire.com/672446/Amphastar-Pharmaceuticals-to-Present-at-the-Jefferies-London-Healthcare-Conference

FAQ

What is Amphastar Pharmaceuticals' participation in the Jefferies London Healthcare Conference?

Amphastar Pharmaceuticals will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on November 18, 2021.

When will the Amphastar conference presentation be available?

The pre-recorded presentation by Amphastar will be available on November 18, 2021, at 8:00 am GMT.

How long will the Amphastar conference webcast be accessible?

The webcast of Amphastar's presentation will be accessible for 90 days following the event.

Who are the key executives presenting Amphastar at the conference?

Key executives presenting include Bill Peters (CFO), Dan Dischner (VP of Corporate Communications), Tony Marrs (SVP Regulatory Affairs), and Jacob Liawatidewi (EVP Corporate Administration and Sales & Marketing).

What are the main products of Amphastar Pharmaceuticals?

Amphastar focuses on developing generic and proprietary injectable, inhalation, and intranasal products, primarily for hospital and urgent care settings.

Amphastar Pharmaceuticals, Inc.

NASDAQ:AMPH

AMPH Rankings

AMPH Latest News

AMPH Stock Data

2.49B
48.68M
22.33%
73.27%
8.65%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
RANCHO CUCAMONGA